Incyte CMO Steven H. Stein Reports Stock Sale and Receives New Equity Awards on July 16, 2026

Details on Stock Sale and Ownership Position

Steven H. Stein, in his role as Chief Medical Officer and Head of Late-Stage Development at Incyte Corporation, sold 1,877 shares of common stock on July 16, 2026, at $114.73 per share. After this transaction, his direct beneficial ownership stood at 21,118 shares. The filing notes no indirect beneficial ownership arrangements.

This sale aligns with typical portfolio management by executives, with no commentary provided on timing or motivation. Investors often interpret such insider sales within the broader context of executive compensation cycles and company performance, though the filing itself offers no specific guidance.

Restricted Stock Units and Four-Year Vesting Schedule

On July 16, 2026, Incyte granted Stein 9,798 restricted stock units (RSUs) as part of his compensation. These RSUs vest at 25% annually over four years, with settlement exclusively in common stock on a one-for-one basis.

Including these RSUs, Stein holds a total of 29,338 shares issuable through outstanding restricted stock and performance stock units yet to vest. This equity package serves as a long-term retention incentive, linking his financial interests to Incyte’s sustained operational success. The four-year vesting is standard in biopharma to promote executive continuity.

Performance Shares and Total Shareholder Return Criteria

Stein also received 24,496 performance shares on July 16, 2026, vesting over three years. Each share can convert into up to 200% of a common share, contingent on Incyte’s relative total shareholder return compared to a defined peer group. The performance period spans January 1, 2026, through December 31, 2028, with vesting on the third anniversary of the grant date, conditional on continued employment.

This structure aligns executive pay with shareholder value creation relative to competitors. While the specific peer group and thresholds are detailed in the Performance Share Award Agreement, they are not included in the Form 4 filing. The maximum 200% payout incentivizes superior market performance.

Stock Options with 10-Year Exercise Term

Incyte granted Stein 42,298 stock options on July 16, 2026, at an exercise price of $116.65 per share, expiring July 15, 2036. Vesting begins with a 25% cliff after one year, followed by monthly vesting over the next three years, totaling a four-year vesting period.

The 10-year exercise window is typical in biopharma equity plans. The exercise price reflects the stock price at grant. Stein holds these options directly, with no indirect ownership noted.

Overview of Incyte’s Executive Compensation Strategy

Stein’s disclosed compensation package illustrates Incyte’s multi-faceted approach to executive incentives, combining time-based RSUs, performance shares, and stock options. This mix aligns management and shareholder interests across different timelines and performance metrics.

The equity-heavy structure supports retention of key medical and development leaders, reflecting the critical role of Stein’s position in drug development and regulatory strategy at Incyte.

Beneficial Ownership and Regulatory Compliance

After all transactions on July 16, 2026, Stein directly owned 21,118 shares and held vested and unvested equity awards. As an officer subject to Section 16 reporting under the Securities Exchange Act of 1934, Stein’s transactions were publicly disclosed within the required two business days.

The filing, submitted on July 20, 2026, lists Stein’s primary residence as Wilmington, Delaware, home to significant Incyte operations. This regulatory framework ensures transparency of insider trading and executive compensation.

Transaction Timing and Market Valuation Context

The share sale and equity grants occurred simultaneously on July 16, 2026, a common practice aligned with fixed annual grant schedules. The filing does not clarify whether the sale was pre-planned or discretionary.

The sale price of $114.73 and option exercise price of $116.65 reflect the stock’s valuation on grant date. No forward-looking statements or business outlook commentary were included in the filing. Investors should consult Incyte’s other public disclosures for broader context.

Equity Award Settlement and Exercise Terms

Stein’s RSUs convert one-for-one into common stock upon vesting, without cash settlement options. Performance shares depend on meeting relative performance goals over three years. Stock options grant the right to buy shares at a fixed price with a 10-year exercise window, allowing flexibility based on market and tax considerations.

This diversified equity portfolio exposes Stein to multiple dimensions of Incyte’s stock performance over time.

Insider Disclosure Requirements and Investor Insight

The Form 4 filing fulfills Stein’s obligation to report beneficial ownership changes within two business days. The SEC’s public database enables investors to track insider transactions across public companies, aiding assessment of management confidence and capital allocation.

Investors typically evaluate insider sales alongside market conditions and company news. However, equity grants on fixed schedules may not signal insider sentiment as clearly as discretionary trades. The filing contains no management commentary, requiring independent investor analysis.

Compliance Measures and Trading Plan Indications

Elizabeth Feeney, acting as Attorney-in-Fact for Stein, filed the disclosure on July 20, 2026. The document includes certifications on accuracy and warnings about penalties for false statements. A checkbox indicates at least one transaction was executed under a Rule 10b5-1 trading plan, providing a safe harbor against insider trading allegations.

Rule 10b5-1 plans allow prearranged trades at predetermined times or prices, demonstrating compliance with insider trading regulations. The filing adheres to SEC formatting standards for officer beneficial ownership disclosures.